DaVita Inc. (DVA) Stock Analysis
Breakout setup
Healthcare · Medical Care Facilities
Sell if holding. Analyst target reached at $151.98 — A.R:R is negative (-2.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: commercial payors.
DaVita is the largest U.S. dialysis provider treating ESKD patients at outpatient centers, with additional international operations in 585 centers across 14 countries and an integrated kidney care business serving 66,000 patients in risk-based arrangements. Revenue is driven by... Read more
Sell if holding. Analyst target reached at $151.98 — A.R:R is negative (-2.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: commercial payors. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Score 5.5/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomercommercial payors10-K Item 1A: 'The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $151.98 — A.R:R is negative (-2.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: commercial payors. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Prior stop was $144.47. Score 5.5/10, moderate confidence.
Take-profit target: $153.03 (+1.0% upside). Prior stop was $144.47. Stop-loss: $144.47.
Concentration risk — Customer: commercial payors; Analyst target reached - limited upside remaining; Near 52-week high (5.0% away).
DaVita Inc. trades at a P/E of 16.0 (forward 9.3). TrendMatrix value score: 7.6/10. Verdict: Sell.
14 analysts cover DVA with a consensus score of 3.4/5. Average price target: $152.
What does DaVita Inc. do?DaVita is the largest U.S. dialysis provider treating ESKD patients at outpatient centers, with additional...
DaVita is the largest U.S. dialysis provider treating ESKD patients at outpatient centers, with additional international operations in 585 centers across 14 countries and an integrated kidney care business serving 66,000 patients in risk-based arrangements. Revenue is driven by dialysis treatment fees, with commercial insurers generating virtually all profit.